Lactobacilli possess inhibitory activity against dipeptidyl peptidase-4 (DPP-4)

Annals of Microbiology

Volumn 66, Issue 1, 2016, Pages 505-509

  Panwar, Harsh ^a,b   Calderwood, Danielle ^a   Grant, Irene R ^a   Grover, Sunita ^c   Green, Brian D ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b GURU ANGAD DEV VETERINARY AND ANIMAL SCIENCES UNIVERSITY   (India)

^c NATIONAL DAIRY RESEARCH INSTITUTE   (India)

Author keywords

Amino methyl coumarin; Dipeptidyl peptidase 4; Glucagon like peptide 1; Glucose dependent insulinotropic peptide; Lactic acid bacteria; Lactobacillus

Indexed keywords

EID: 84957956765     PISSN: 15904261     EISSN: 18692044     Source Type: Journal    
DOI: 10.1007/s13213-015-1129-7     Document Type: Article

References (25)

1. Abe M, Akiyama T, Umezawa Y, Yamamoto K, Nagai M, Yamazaki H, Ichikawa Y, Muraoka Y (2005) Synthesis and biological activity of sulphostin analogues, novel dipeptidyl peptidase IV inhibitors. Bioorg Med Chem 13:785–797
2. Al-Masri IM, Mohammad MK, Tahaa MO (2009) Inhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycemic effect of berberine. J Enzyme Inhib Med Chem 24:1061–1066
3. Bockelmann W, Fobker M (1991) Purification and characterization of the X-prolyldipeptidyl-aminopeptidase from Lactobacillus delbrueckii subsp. bulgaricus and Lactobacillus acidophilus. Int Dairy J 1:51–66
4. Chapman TM, Plosker GL, Figgitt DP (2007) Spotlight on VSL#3 probiotic mixture in chronic inflammatory bowel diseases. Bio Drugs 21:61–63
5. Deacon CF, Holst JJ (2013) Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety. Expert Opin Pharmacother 14:2047–2058
6. Flatt PR, Bailey CJ, Green BD (2008) Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes. Front Biosci 13:3648–3660
7. Fujiwara K, Tsuru D (1978) New chromogenic and fluorogenic substrates for pyrrolidonyl peptidase. J Biochem 83:1145–1149
8. Green BD, Flatt PR, Bailey CJ (2006a) Dipeptidylpeptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes. Diab Vasc Dis Res 3:159–165
9. Green BD, Flatt PR, Bailey CJ (2006b) Inhibition of dipeptidyl peptidase IV activity as therapy of diabetes. Expert Opin Emerg Drugs 11:525–539
10. Habibi-Najafi MB, Lee BH (1994) Purification and characterization of the X prolyldipeptidyl peptidase from Lactobacillus casei subsp. casei LGG. Appl Microbiol Biotechnol 42:280–286
11. Huang SL, Jao CL, Ho KP, Hsu KC (2008) Dipeptidyl-peptidase IV inhibitory activity of peptides derived from tuna cooking juice hydrolysates. Peptides 35:114–121
12. Huebner C, Ding Y, Petermann I, Knapp C, Ferguson LR (2011) The probiotic Escherichia coli Nissle 1917 reduces pathogen invasion and modulates cytokine expression in Caco-2 cells infected with Crohn’s disease-associated E. coli LF82. Appl Environ Microbiol 77:2541–2544
13. Lacroix IME, Li-Chan ECY (2012) Dipeptidyl peptidase – IV inhibitory activity of dairy protein hydrolysates. Int Dairy J 25:97–102
14. Lendeckel U, Arndt M, Wolke C, Reinhold D, Kahne T, Ansorge S (2002) Inhibition of human leukocyte function, alanylaminopeptidase (APN, CD13) and dipeptidylpeptidase IV (DP IV, CD 26) enzymatic activities by aqueous extracts of Cistus incanus L. ssp. incanus. J Ethnopharmacol 79:221–227
15. Magboul AAA, McSweeney PLH (2000) Purification and characterization of the X-prolyl-dipeptidyl-aminopeptidase from Lactobacillus curvatus DPC2024. Dairy Sci Technol 80:385–396
16. Meyer-Barton EC, Klein JR, Imam M, Plapp R (1993) Cloning and sequence analysis of the X-prolyl-dipeptidyl-aminopeptidase gene (pepX) from Lactobacillus delbruckii ssp. lactis DSM 7290. Appl Microbiol Biotechnol 40:82–89
17. Nongonierma AB, Fitzgerald RJ (2013) Inhibition of depeptidyl peptidase IV (DPP IV) by proline containing casein-derived peptides. J Funct Foods 5:1909–1917
18. Panwar H, Rashmi HM, Batish VK, Grover S (2013) Probiotics as potential biotherapeutics in the management of type 2 diabetes – prospects and perspectives. Diabetes Metab Res Rev 29:103–112
19. Panwar H, Calderwood D, Grant IR, Grover S, Green BD (2014) Lactobacillus strains isolated from infant faeces possess potent inhibitory activity against intestinal alpha- and beta glucosidases suggesting anti-diabetic potential. Eur J Nutr. doi:10.1007/s00394-013-0649-9
20. Parmar HS, Jain P, Chauhan DS, Bhinchar MK, Munjal V, Yusuf M, Choube K, Tawani A, Tiwari V, Manivanna KA (2012) DPP-IV inhibitory potential of naringin: An in silico, in vitro and in vivo study. Diabetes Res Clin Pract 97:105–111
21. Ritchie ML, Romanuk TN (2012) A meta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS ONE 7:e34938
22. Savijoki K, Ingmer H, Vermanen P (2006) Proteolytic systems of lactic acid bacteria. Appl Microbiol Biotechnol 71:394–406
23. Scheen AJ (2013) Cardiovascular effects of gliptins. Nat Rev Cardiol 10:73–84
24. Selkrig J, Wong P, Zhang X, Pettersson S (2014) Metabolic tinkering by the gut microbiome. Gut Microbes 5:369–350
25. Umezawa H (1984) Studies on low molecular weight immunomodifiers produced by microorganisms: results of ten years effort. Clin Infect Dis 6:412–420